Zoltán Balikó
About
In The Last Decade
Zoltán Balikó
16 papers receiving 211 citations
Peers
Comparison fields: 5 of 40
- Pulmonary and Respiratory Medicine 130
- Oncology 104
- Immunology 47
- Infectious Diseases 39
- Molecular Biology 28
Countries citing papers authored by Zoltán Balikó
This map shows the geographic impact of Zoltán Balikó's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoltán Balikó with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoltán Balikó more than expected).
Fields of papers citing papers by Zoltán Balikó
This network shows the impact of papers produced by Zoltán Balikó. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoltán Balikó. The network helps show where Zoltán Balikó may publish in the future.
Co-authorship network of co-authors of Zoltán Balikó
This figure shows the co-authorship network connecting the top 25 collaborators of Zoltán Balikó. A scholar is included among the top collaborators of Zoltán Balikó based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoltán Balikó. Zoltán Balikó is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 13 | |
| 2 | 4 | |
| 3 | 9 | |
| 4 | [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma]. | 1 |
| 5 | 2 | |
| 6 | Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial | 17 |
| 7 | 3 | |
| 8 | 7 | |
| 9 | 107 | |
| 10 | The role of Vdelta2+T-cells in patients with active Mycobacterium tuberculosis infection and tuberculin anergy. | 9 |
| 11 | 0 | |
| 12 | 25 | |
| 13 | 9 | |
| 14 | [Chronic obstructive respiratory diseases: diagnosis and therapy]. | 1 |
| 15 | 1 | |
| 16 | 7 | |
| 17 | [Prognostic role of immunoglobulin levels in chronic B cell lymphoid leukemia]. | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.